Today, Bruce Campbell (1) and David Cockfield commented about whether XEC-T, ZLU-T, ZLB-T, TD-T, TECK.B-T, NFLX-Q, BIP.UN-T, T-T, GGB-T, BCE-T, BNS-T, XEG-T, SVR-T, ZWE-T, CU-T, ENB-T, XIT-T, EQX-T, SLF-T, BPY.UN-T, SHOP-T, WCN-T, BB-T, AQN-T, HBM-T, BNS-T, FNV-T, CTST-Q, V-N, MFC-T, ENB-T, BTE-T, PWF-T, SPB-T, S-T, NTR-T, SHOP-T, MG-T, T-T, CJR.B-T, CNR-T are stocks to buy or sell.
A pure growth story. It's been a stellar performer for him. Though it trades at over 30x earnings and pays only a 0.56% yield, you buy this for growth in the coming years. Visa is also in a tech ETF in the U.S. which helps the stock. (Analysts’ price target is $184.84)
(opening comment) They raised an amount of cash at their initial offering, so look at the amount of cash per share. Maybe step in near its cash value. You'd be paying nothing for the business. But he doesn't know the specific values and he is only marginally invested in cannabis. There's a risk CTST will lose all its medical customers, so maybe stick closely to the cash value. He owns MediPharm Labs Corp. in this space.